U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT07495098) titled 'Phase 1B Trial of Intratumoral Cisplatin for Stage IV Lung Cancer' on March 20.
Brief Summary: The addition of intravenous (given through a vein) cisplatin to immunotherapy improves treatment outcomes for lung cancer, but unfortunately results in significantly more side effects since the rest of the body is exposed to significant amounts of the drug. Our clinical trial data indicate that injecting cisplatin directly into the tumor using a bronchoscope (a small flexible tube with a camera in it) has very few side effects, and results in significant cell death and potentially improvement in the immune response. The goal of this propo...